

Superior Platform for Enhancement of Antibodies

	Technology	Binding Affinity	Potential Immunogenicity	Homogeneity Benefit	Economic Benefit
BIOLEX+ THERAPEUTICS	Stable RNAi	✓✓✓	No	Yes	+++
Mammalian Cells (CHO)	GnTIII over expression FucT knock out	✓✓✓	No	No	+
Yeast	Glycan remodeling	✓✓✓	??	No	++
Amino Acid Mutation	Fc Mutation	✓to ✓✓	Yes	No	No
<i>E. coli</i>	Unable to produce glycosylated monoclonal antibodies				
Other higher plants	Systems have not demonstrated glycosylation optimization				